Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Camurus AB ( (SE:CAMX) ) has shared an update.
Camurus reported strong full-year 2025 results, with total revenues up 21% to SEK 2.27 billion, product sales up 6%, and royalties up 87%, driving a 69% rise in profit before tax to SEK 933 million and a 31% increase in net cash to SEK 3.7 billion. The fourth quarter showed a 16% revenue decline and weaker profit versus the prior year, largely explained by a one-off UK inventory repurchase tied to a distribution model change, while operating expenses fell and the balance sheet remained robust.
Strategically, the company advanced its endocrine and metabolic portfolio, launching Oczyesa for acromegaly in Germany, resubmitting the US regulatory filing for Oclaiz in acromegaly, and reporting positive Phase 1b data for a monthly semaglutide depot in overweight or obese participants. A new collaboration and license agreement with Gubra to develop a long-acting hypoparathyroidism treatment broadens Camurus’s endocrine footprint, supporting future growth prospects and reinforcing its positioning in long-acting therapies despite short-term quarterly volatility.
The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK760.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
More about Camurus AB
Camurus AB is an international, science-led biopharmaceutical company that develops and commercializes long-acting medicines for severe and chronic diseases using its proprietary FluidCrystal technology. The company’s R&D pipeline targets dependence, pain, cancer, and endocrine disorders, and it operates across Europe, the US, and Australia with headquarters in Lund, Sweden, and shares listed on Nasdaq Stockholm under the ticker CAMX.
Its portfolio and pipeline are geared toward best-in-class, long-acting therapies, including recently advanced endocrine products such as Oczyesa for acromegaly and depot formulations like semaglutide CAM2056 for obesity. This positions Camurus in specialized, high-value therapeutic niches where long-acting delivery can offer clinical and commercial advantages over conventional treatments.
Average Trading Volume: 114,106
Technical Sentiment Signal: Strong Buy
Current Market Cap: SEK41.5B
For a thorough assessment of CAMX stock, go to TipRanks’ Stock Analysis page.